Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GLTO 
Galecto Inc (GLTO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: GLTO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $32
1 Year Target Price $32
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -83.84% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 30.80M USD | Price to earnings Ratio - | 1Y Target Price 32 |
Price to earnings Ratio - | 1Y Target Price 32 | ||
Volume (30-day avg) 2 | Beta 1.54 | 52 Weeks Range 2.01 - 33.60 | Updated Date 12/3/2025 |
52 Weeks Range 2.01 - 33.60 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13.18 |
Earnings Date
Report Date 2025-11-07 | When - | Estimate - | Actual -2.3609 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.54% | Return on Equity (TTM) -109.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22122023 | Price to Sales(TTM) - |
Enterprise Value 22122023 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.46 | Shares Outstanding 1592521 | Shares Floating 1211028 |
Shares Outstanding 1592521 | Shares Floating 1211028 | ||
Percent Insiders 3.57 | Percent Institutions 13.38 |
Upturn AI SWOT
Galecto Inc
Company Overview
History and Background
Galecto, Inc. is a biotechnology company focused on developing novel treatments for fibrosis and cancer. Founded in 2011, it has progressed through various preclinical and clinical stages, focusing on galectin modulators.
Core Business Areas
- Fibrosis Drug Development: Focuses on developing small molecule inhibitors of galectin-3 for the treatment of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH).
- Cancer Drug Development: Explores galectin modulators for oncology applications, aiming to enhance immune responses against cancer.
Leadership and Structure
Dr. Hans Schambye is the CEO. The organizational structure consists of research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- GB0139 (Inhaled Galectin-3 Inhibitor): Developed for the treatment of idiopathic pulmonary fibrosis (IPF). Currently in clinical trials. Market share not yet applicable due to pre-commercial stage. Competitors include Boehringer Ingelheim (Ofev), Roche (Esbriet).
- GB1211 (Oral Galectin-3 Inhibitor): Developing for NASH and other fibrotic diseases. Currently in clinical trials. Market share not yet applicable due to pre-commercial stage. Competitors are diverse and include companies developing various NASH treatments, such as Madrigal Pharmaceuticals (Resmetirom).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investment in research and development. Fibrosis and oncology are areas of substantial unmet medical need and growing markets.
Positioning
Galecto is positioned as a developer of novel galectin-3 inhibitors, targeting the underlying mechanisms of fibrosis and cancer. Its competitive advantage lies in its specific galectin-3 modulation technology.
Total Addressable Market (TAM)
The total addressable market for IPF and NASH is substantial, estimated to be billions of dollars. Galecto is positioned to capture a portion of this market if its drugs are successfully developed and commercialized.
Upturn SWOT Analysis
Strengths
- Novel galectin-3 inhibition technology
- Experienced management team
- Clinical-stage pipeline
- Strong intellectual property position
Weaknesses
- Limited financial resources
- Dependence on clinical trial outcomes
- Lack of commercialized products
- High attrition rate in drug development
Opportunities
- Potential partnerships with larger pharmaceutical companies
- Expansion of pipeline into other fibrotic diseases
- Successful clinical trial results
- Advancements in understanding of galectin-3 biology
Threats
- Clinical trial failures
- Competition from other companies
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- BI (N/A)
- Roche (ROG.SW)
- Madrigal Pharmaceuticals (MDGL)
Competitive Landscape
Galecto faces competition from large pharmaceutical companies with established products and significant resources. Galecto's advantage lies in its novel approach to targeting galectin-3.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by R&D investment, not revenue generation.
Future Projections: Future growth depends on the success of clinical trials and potential commercialization of its drugs. Analyst projections vary.
Recent Initiatives: Focusing on advancing GB0139 and GB1211 through clinical trials and securing partnerships.
Summary
Galecto Inc. is a clinical-stage biopharmaceutical company pioneering galectin-3 inhibition for fibrosis and cancer. While its technology is innovative and clinical trials are progressing, the company faces significant financial challenges and competition. Success hinges on positive clinical trial outcomes and strategic partnerships. The company should closely monitor cash burn and competition to enhance the value for its shareholders.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Galecto Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-10-29 | Co-Founder, President, CEO & Director Dr. Hans T. Schambye M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://galecto.com |
Full time employees 5 | Website https://galecto.com | ||
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.